Christian C. Felder

Affiliations: 
University of Maryland Dental School, Baltimore, MD, United States 
Google:
"Christian Felder"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Montani C, Canella C, Schwarz AJ, et al. (2020) The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Coussens NP, Sittampalam GS, Jonson SG, et al. (2019) The Opioid Crisis and the Future of Addiction and Pain Therapeutics. The Journal of Pharmacology and Experimental Therapeutics
Felder CC. (2019) GPCR drug discovery-moving beyond the orthosteric to the allosteric domain. Advances in Pharmacology (San Diego, Calif.). 86: 1-20
Hollingsworth SA, Kelly B, Valant C, et al. (2019) Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs. Nature Communications. 10: 3289
Knopp KL, Simmons RMA, Guo W, et al. (2019) Modulation of TARP γ8-containing AMPA Receptors as a Novel Therapeutic Approach for Chronic Pain. The Journal of Pharmacology and Experimental Therapeutics
Liu X, Thomas CE, Felder CC. (2019) The innovation ecosystem: an analysis of a decade of approved and failed drugs. International Journal of Pharmaceutics
Broad LM, Sanger HE, Mogg AJ, et al. (2018) Identification and pharmacological profile of SPP1, a potent, functionally selective and brain penetrant M1 muscarinic acetylcholine receptor agonist. British Journal of Pharmacology
Bradley SJ, Molloy C, Bundgaard C, et al. (2018) Bitopic binding mode of an M1 muscarinic acetylcholine receptor agonist associated with adverse clinical trial outcomes. Molecular Pharmacology
Mogg AJ, Eessalu T, Johnson M, et al. (2018) pharmacological characterization and validation of LSN3172176 a novel M1 selective muscarinic receptor agonist tracer molecule for positron emission tomography (PET). The Journal of Pharmacology and Experimental Therapeutics
Felder CC, Goldsmith PJ, Jackson K, et al. (2018) Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases. Neuropharmacology
See more...